These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 36098051)

  • 1. Effects of Empagliflozin in Women and Men With Heart Failure and Preserved Ejection Fraction.
    Butler J; Filippatos G; Siddiqi TJ; Ferreira JP; Brueckmann M; Bocchi E; Böhm M; Chopra VK; Giannetti N; Iwata T; Januzzi JL; Kaul S; Piña IL; Ponikowski P; Rauch-Kröhnert U; Shah SJ; Senni M; Sumin M; Verma S; Zhang J; Pocock SJ; Zannad F; Packer M; Anker SD
    Circulation; 2022 Oct; 146(14):1046-1055. PubMed ID: 36098051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Empagliflozin, Health Status, and Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial.
    Butler J; Filippatos G; Jamal Siddiqi T; Brueckmann M; Böhm M; Chopra VK; Pedro Ferreira J; Januzzi JL; Kaul S; Piña IL; Ponikowski P; Shah SJ; Senni M; Vedin O; Verma S; Peil B; Pocock SJ; Zannad F; Packer M; Anker SD
    Circulation; 2022 Jan; 145(3):184-193. PubMed ID: 34779658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Empagliflozin for Heart Failure With Preserved Left Ventricular Ejection Fraction With and Without Diabetes.
    Filippatos G; Butler J; Farmakis D; Zannad F; Ofstad AP; Ferreira JP; Green JB; Rosenstock J; Schnaidt S; Brueckmann M; Pocock SJ; Packer M; Anker SD;
    Circulation; 2022 Aug; 146(9):676-686. PubMed ID: 35762322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF).
    Lee MMY; Brooksbank KJM; Wetherall K; Mangion K; Roditi G; Campbell RT; Berry C; Chong V; Coyle L; Docherty KF; Dreisbach JG; Labinjoh C; Lang NN; Lennie V; McConnachie A; Murphy CL; Petrie CJ; Petrie JR; Speirits IA; Sourbron S; Welsh P; Woodward R; Radjenovic A; Mark PB; McMurray JJV; Jhund PS; Petrie MC; Sattar N
    Circulation; 2021 Feb; 143(6):516-525. PubMed ID: 33186500
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of empagliflozin in heart failure with preserved ejection fraction according to frailty status in EMPEROR-Preserved.
    Coats AJS; Butler J; Tsutsui H; Doehner W; Filippatos G; Ferreira JP; Böhm M; Chopra VK; Verma S; Nordaby M; Iwata T; Nitta D; Ponikowski P; Zannad F; Packer M; Anker SD
    J Cachexia Sarcopenia Muscle; 2024 Feb; 15(1):412-424. PubMed ID: 38158636
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and Efficacy of Empagliflozin and Diuretic Use in Patients with Heart Failure and Preserved Ejection Fraction: A Post Hoc Analysis of the EMPEROR-Preserved Trial.
    Butler J; Usman MS; Filippatos G; Ferreira JP; Böhm M; Brueckmann M; Januzzi JL; Kaul S; Piña IL; Ponikowski P; Senni M; Sumin M; Verma S; Zaremba-Pechmann L; Pocock SJ; Packer M; Anker S
    JAMA Cardiol; 2023 Jul; 8(7):640-649. PubMed ID: 37223933
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sex Differences in Characteristics, Outcomes, and Treatment Response With Dapagliflozin Across the Range of Ejection Fraction in Patients With Heart Failure: Insights From DAPA-HF and DELIVER.
    Wang X; Vaduganathan M; Claggett BL; Hegde SM; Pabon M; Kulac IJ; Vardeny O; O'Meara E; Zieroth S; Katova T; McGrath MM; Pouleur AC; Jhund PS; Desai AS; Inzucchi SE; Kosiborod MN; de Boer RA; Kober L; Sabatine MS; Martinez FA; Ponikowski P; Shah SJ; Hernandez AF; Langkilde AM; McMurray JJV; Solomon SD; Lam CSP
    Circulation; 2023 Feb; 147(8):624-634. PubMed ID: 36342789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of Dapagliflozin in Men and Women With Heart Failure With Reduced Ejection Fraction: A Prespecified Analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure Trial.
    Butt JH; Docherty KF; Petrie MC; Schou M; Kosiborod MN; O'Meara E; Katova T; Ljungman CEA; Diez M; Ogunniyi MO; Langkilde AM; Sjöstrand M; Lindholm D; Bengtsson O; Martinez FA; Ponikowski P; Sabatine MS; Solomon SD; Jhund PS; McMurray JJV; Køber L
    JAMA Cardiol; 2021 Jun; 6(6):678-689. PubMed ID: 33787831
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blinded Withdrawal of Long-Term Randomized Treatment With Empagliflozin or Placebo in Patients With Heart Failure.
    Packer M; Butler J; Zeller C; Pocock SJ; Brueckmann M; Ferreira JP; Filippatos G; Usman MS; Zannad F; Anker SD
    Circulation; 2023 Sep; 148(13):1011-1022. PubMed ID: 37621153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction.
    Butler J; Packer M; Filippatos G; Ferreira JP; Zeller C; Schnee J; Brueckmann M; Pocock SJ; Zannad F; Anker SD
    Eur Heart J; 2022 Feb; 43(5):416-426. PubMed ID: 34878502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Empagliflozin, irrespective of blood pressure, improves outcomes in heart failure with preserved ejection fraction: the EMPEROR-Preserved trial.
    Bhm M; Anker S; Mahfoud F; Lauder L; Filippatos G; Ferreira JP; Pocock SJ; Brueckmann M; Saloustros I; Schler E; Wanner C; Zannad F; Packer M; Butler J
    Eur Heart J; 2023 Feb; 44(5):396-407. PubMed ID: 36478225
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Empagliflozin Effects on Pulmonary Artery Pressure in Patients With Heart Failure: Results From the EMBRACE-HF Trial.
    Nassif ME; Qintar M; Windsor SL; Jermyn R; Shavelle DM; Tang F; Lamba S; Bhatt K; Brush J; Civitello A; Gordon R; Jonsson O; Lampert B; Pelzel J; Kosiborod MN
    Circulation; 2021 Apr; 143(17):1673-1686. PubMed ID: 33550815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial.
    Nassif ME; Windsor SL; Tang F; Khariton Y; Husain M; Inzucchi SE; McGuire DK; Pitt B; Scirica BM; Austin B; Drazner MH; Fong MW; Givertz MM; Gordon RA; Jermyn R; Katz SD; Lamba S; Lanfear DE; LaRue SJ; Lindenfeld J; Malone M; Margulies K; Mentz RJ; Mutharasan RK; Pursley M; Umpierrez G; Kosiborod M
    Circulation; 2019 Oct; 140(18):1463-1476. PubMed ID: 31524498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Empagliflozin Improves Outcomes in Patients With Heart Failure and Preserved Ejection Fraction Irrespective of Age.
    Böhm M; Butler J; Filippatos G; Ferreira JP; Pocock SJ; Abdin A; Mahfoud F; Brueckmann M; Gollop ND; Iwata T; Ponikowski P; Wanner C; Zannad F; Packer M; Anker SD;
    J Am Coll Cardiol; 2022 Jul; 80(1):1-18. PubMed ID: 35772911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Dapagliflozin Versus Placebo on Symptoms and 6-Minute Walk Distance in Patients With Heart Failure: The DETERMINE Randomized Clinical Trials.
    McMurray JJV; Docherty KF; de Boer RA; Hammarstedt A; Kitzman DW; Kosiborod MN; Maria Langkilde A; Reicher B; Senni M; Shah SJ; Wilderäng U; Verma S; Solomon SD
    Circulation; 2024 Mar; 149(11):825-838. PubMed ID: 38059368
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Associations of Empagliflozin With Left Ventricular Volumes, Mass, and Function in Patients With Heart Failure and Reduced Ejection Fraction: A Substudy of the Empire HF Randomized Clinical Trial.
    Omar M; Jensen J; Ali M; Frederiksen PH; Kistorp C; Videbæk L; Poulsen MK; Tuxen CD; Möller S; Gustafsson F; Køber L; Schou M; Møller JE
    JAMA Cardiol; 2021 Jul; 6(7):836-840. PubMed ID: 33404637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Empagliflozin in Heart Failure With Reduced Ejection Fraction in Patients With Ischemic Versus Nonischemic Cause.
    Khan MS; Butler J; Anker SD; Filippatos G; Ferreira JP; Pocock SJ; Januzzi JL; Piña IL; Böhm M; Ponikowski P; Verma S; Brueckmann M; Vedin O; Zeller C; Zannad F; Packer M
    J Am Heart Assoc; 2023 Jan; 12(1):e027652. PubMed ID: 36565199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Empagliflozin on Heart Failure Outcomes After Acute Myocardial Infarction: Insights From the EMPACT-MI Trial.
    Hernandez AF; Udell JA; Jones WS; Anker SD; Petrie MC; Harrington J; Mattheus M; Seide S; Zwiener I; Amir O; Bahit MC; Bauersachs J; Bayes-Genis A; Chen Y; Chopra VK; A Figtree G; Ge J; G Goodman S; Gotcheva N; Goto S; Gasior T; Jamal W; Januzzi JL; Jeong MH; Lopatin Y; Lopes RD; Merkely B; Parikh PB; Parkhomenko A; Ponikowski P; Rossello X; Schou M; Simic D; Steg PG; Szachniewicz J; van der Meer P; Vinereanu D; Zieroth S; Brueckmann M; Sumin M; Bhatt DL; Butler J
    Circulation; 2024 May; 149(21):1627-1638. PubMed ID: 38581389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment effects of empagliflozin in hospitalized heart failure patients across the range of left ventricular ejection fraction - Results from the EMPULSE trial.
    Tromp J; Kosiborod MN; Angermann CE; Collins SP; Teerlink JR; Ponikowski P; Biegus J; Ferreira JP; Nassif ME; Psotka MA; Brueckmann M; Blatchford JP; Steubl D; Voors AA
    Eur J Heart Fail; 2024 Apr; 26(4):963-970. PubMed ID: 38572654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial.
    Packer M; Butler J; Zannad F; Filippatos G; Ferreira JP; Pocock SJ; Carson P; Anand I; Doehner W; Haass M; Komajda M; Miller A; Pehrson S; Teerlink JR; Schnaidt S; Zeller C; Schnee JM; Anker SD
    Circulation; 2021 Oct; 144(16):1284-1294. PubMed ID: 34459213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.